Filed Pursuant to Rule 424(b)(3)
Registration No. 333-180650
Prospectus Supplement No. 4
(to prospectus dated May 2, 2012)
This Prospectus Supplement No. 4 supplements and amends the prospectus dated May 2, 2012, or the Original Prospectus, and the
other Prospectus Supplements thereto, dated May 10, 2012, June 11, 2012 and June 19, 2012, which we refer to collectively as the Prospectus. The Prospectus relates to the sale of an aggregate of 20,819,468 shares of our
common stock, $0.0001 par value per share, by the selling stockholders identified in the Original Prospectus, including their transferees, pledgees, donees or successors.
On July 26, 2012, we filed with the Securities and Exchange Commission a Current Report on Form 8-K
relating to the approval of RAYOS
®
by the U.S. Food and Drug Administration. The information set forth below
supplements and amends the information contained in the Prospectus. This Prospectus Supplement No. 4 should be read in conjunction with, and delivered with, the Prospectus and is qualified by reference to the Prospectus except to the extent
that the information in this Prospectus Supplement No. 4 supersedes the information contained in the Prospectus.
The
selling stockholders may sell their shares of common stock from time to time at market prices prevailing at the time of sale, at prices related to the prevailing market price, or at negotiated prices. We will not receive any proceeds from the sale
of common stock by the selling stockholders, other than as a result of the exercise of warrants held by the selling stockholders for cash.
No underwriter or other person has been engaged to facilitate the sale of shares of our common stock in this offering. We have paid the cost of registering the shares of common stock covered by the
Prospectus as well as various related expenses. The selling stockholders are responsible for all selling commissions, transfer taxes and other costs related to the offer and sale of their shares of common stock.
Our common stock is traded on The NASDAQ Global Market under the symbol “HZNP.” On July 24, 2012, the closing sale price
of our common stock on The NASDAQ Global Market was $7.56 per share.
This investment
involves risks. See “
Risk Factors
” on page 10 of the Original Prospectus, as updated by the supplements thereto.
Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this Prospectus Supplement No. 4 is truthful or complete. Any representation to the contrary is a
criminal offense.
The date of this Prospectus Supplement No. 4 is July 26, 2012.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): July 26, 2012
Horizon Pharma, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-35238
|
|
27-2179987
|
|
(State of
incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
520 Lake Cook Road, Suite 520, Deerfield, Illinois
|
|
60015
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (224) 383-3000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On July 26, 2012, the U.S. Food and Drug Administration approved
RAYOS
®
(prednisone) delayed-release tablets (1 mg, 2 mg and 5 mg) for the treatment of a broad range of diseases
including rheumatoid arthritis, or RA, polymyalgia rheumatica, or PMR, psoriatic arthritis, or PsA, ankylosing spondylitis, or AS, asthma and chronic obstructive pulmonary disease, or COPD.
The Company expects to commence commercial sales of RAYOS in the United States for rheumatologic diseases such as RA and PMR in the
fourth quarter of 2012. The Company also plans to develop a broader commercial strategy to expand the opportunity for RAYOS in key IL-6 mediated diseases, including asthma and COPD.
The Company issued a press release announcing the approval of RAYOS, a copy of which is attached as Exhibit 99.1 to this report.
Forward-Looking Statements
Statements included in this report that are not a description of historical facts are forward-looking statements, including without limitation statements related to the Company’s plans to
commercialize RAYOS and the timing of commercial sales of RAYOS in the Unites States. Words such as “believes”, “would”, “anticipates”, “plans”, “expects”, “may”, “intend”,
“will”, and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans will be achieved. These
forward-looking statements are based on management’s expectations on the date of this report. Actual results may differ materially from those set forth in this report due to the risks and uncertainties inherent in the Company’s
business including, without limitation, risks regarding the Company’s ability to commercialize products successfully, changes in the Company’s strategy as to when to launch RAYOS in the United States and on which approved indications it
will focus its initial commercial efforts, whether physicians will prescribe and patients will use RAYOS, once available, and competition in the market for RAYOS. For a further description of these and other risks facing the Company, please see the
risk factors described in the Company’s filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in those filings.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
99.1
|
|
Press Release dated July 26, 2012.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Date: July 26, 2012
|
|
|
HORIZON PHARMA, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
|
/s/ Robert J. De Vaere
|
|
|
|
|
|
|
|
Robert J. De Vaere
|
|
|
|
|
|
|
|
Executive Vice President and Chief Financial Officer
|
Exhibit 99.1
Horizon Pharma Announces FDA Approval of RAYOS
®
(prednisone) Delayed-Release Tablets for Rheumatoid Arthritis and Multiple Additional Indications
RAYOS approved for key rheumatology indications such as Rheumatoid Arthritis, Polymyalgia Rheumatica, Psoriatic Arthritis and
Ankylosing Spondylitis.
Deerfield, III. –
July 26, 2012
–
Horizon Pharma, Inc., (NASDAQ:
HZNP) announced today that the U.S. Food and Drug Administration (FDA) has approved
RAYOS
®
(prednisone)
delayed-release tablets (1 mg, 2 mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary
disease (COPD)
(see full
prescribing information at
www.RAYOSrx.com
). The FDA approval was supported by data bridging the pharmacokinetics of RAYOS to immediate-release prednisone and data from the
C
ircadian
A
dministration of
P
rednisone in
RA
(CAPRA-1 and 2) trials. The CAPRA-2 trial demonstrated that people with moderate to severe RA treated with RAYOS experienced a statistically significant improvement in ACR20 response criteria
compared to placebo. The CAPRA-1 trial supported the overall safety of RAYOS.
“We are extremely pleased the FDA has approved RAYOS for a
broad range of indications, including RA and polymyalgia rheumatica,” said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma. “Our initial focus will be on the launch of RAYOS in rheumatologic diseases
such as RA and polymyalgia rheumatica in the fourth quarter of this year. Based on the extent of the approved indications, we will be developing a broader commercial strategy to expand the opportunity for RAYOS in key IL-6 mediated diseases,
including asthma and COPD.”
RAYOS Clinical Data
U.S. New Drug Application
The efficacy of RAYOS in the treatment of RA was assessed in the
CAPRA-2 trial, a double-blind, placebo-controlled, randomized, 12-week trial in patients with active rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR) criteria. Enrolled patients were not currently being treated with
corticosteroids but had received non-biologic disease-modifying antirheumatic drug (DMARD) therapy for at least 6 months prior to receipt of study medication, with an incomplete response to DMARD therapy alone. Patients were randomized in a 2:1
ratio to treatment with RAYOS 5 mg (n=231) or placebo (n=119) administered at 10 p.m. in addition to their DMARD therapy. A total of 350 patients were enrolled and ranged in age from 27 to 80 years (median age 57 years). Patients were predominantly
Caucasian and 84% were female.
Results from CAPRA-2 demonstrated:
|
|
•
|
|
A statistically significant improvement in ACR20 response criteria, the primary study endpoint, for patients who were treated with RAYOS compared to
the placebo group (47% vs. 29%; p-value = 0.001).
|
|
|
•
|
|
A statistically significant improvement in ACR50 response compared to placebo (22% vs. 10%; p-value = 0.007) and an improvement in the more stringent
ACR70 response criteria (7% vs. 3%; p-value = 0.0984). Both ACR50 and ACR70 were pre-specified secondary endpoints.
|
The
relative change from baseline in the duration of morning stiffness at 12 weeks was assessed as a pre-specified secondary endpoint. Patients treated with RAYOS had a median decrease in the duration of morning stiffness of 55 minutes compared to 33
minutes in placebo-treated patients (20 minute estimated median difference between treatment groups with 95% confidence interval [7, 32; p-value = 0.001]).
Results from CAPRA-2 are published in
Annals of the Rheumatic
Diseases
.
1
“Prednisone is a common therapy for patients with various inflammatory diseases, including RA, and the delayed-release enhancement offered with
RAYOS is an important treatment advance,” said Michael Schiff, M.D., Clinical Professor of Medicine at the University of Colorado School of Medicine, Rheumatology Division. “RAYOS is engineered to benefit the underlying patterns of
inflammatory diseases. RAYOS, as studied in its clinical trials with ten p.m. dosing, reduces the overnight rise of inflammatory mediators, which results in less pain and stiffness for patients as they begin their day.”
The safety of RAYOS was based on the evaluation of 375 RA patients in two controlled trials. Patients treated with RAYOS ranged in age from 20 to 80
years (median age 56 years). Patients were predominantly Caucasian and 85% were female.
Included in these safety results were data from the
CAPRA-1 trial, a 12 week, double-blind, placebo-controlled study that evaluated 288 RA patients. CAPRA-1 compared 10 p.m. administration of RAYOS with the morning administration of immediate-release prednisone at the same individual dose (average
dose of 6.7 mg). Following the 12-week CAPRA-1 study, patients were followed in a 9-month, open-label extension study, which included 249 RA patients, 219 of whom completed the extension study. Patients received RAYOS 3 mg to 10 mg once daily at 10
p.m.; the majority (84%) received 5 mg or less.
The clinical trial experience did not raise any safety concerns beyond those already
established for immediate-release prednisone.
Results from the CAPRA-1 12-week study and the 9-month open-label extension
are published in
The Lancet
and
Annals of the Rheumatic Diseases,
respectively.
2,3
About RAYOS
RAYOS, known as LODOTRA
®
in Europe, is a proprietary
delayed-release formulation of low-dose prednisone. The pharmacokinetic profile of RAYOS is different with an approximately four-hour lag time from that of immediate-release prednisone formulations. In clinical trials studying use of RAYOS in RA,
patients were administered RAYOS at 10 p.m. with food. Given RAYOS delayed-release profile, this helps to achieve therapeutic prednisone blood levels at a time point when cytokine levels start rising during the middle of
the night. While the pharmacokinetic profile of RAYOS differs in terms of lag time from immediate-release prednisone, its absorption, distribution and elimination processes are comparable.
RAYOS utilizes SkyePharma’s proprietary Geoclock™ technology.
Outside the United States, LODOTRA is approved for the treatment of moderate to severe active RA when accompanied by morning stiffness in 16 European
countries and Israel. Horizon has granted commercialization rights for LODOTRA in Europe, Asia and Latin America to its distribution partner Mundipharma International Corporation Limited.
Important Safety Information
RAYOS
®
(prednisone) delayed-release tablets
Approved uses of RAYOS
RAYOS, a delayed-release form of prednisone, prevents the release
of substances in the body that cause inflammation. RAYOS is approved to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic
obstructive pulmonary disease (COPD).
For a full list of RAYOS indications, please see full prescribing information at
www.RAYOSrx.com
.
RAYOS is contraindicated in patients who have known hypersensitivity to prednisone or to any of the excipients. Rare instances of anaphylaxis have occurred in patients receiving corticosteroids.
Important information about RAYOS
Do not use RAYOS if you are allergic to prednisone.
Long-term use of RAYOS can affect how your
body responds to stress. Symptoms can include weight gain, severe fatigue, weak muscles, and high blood sugar.
RAYOS can weaken your immune
system, making it easier for you to get an infection or worsening an infection you already have or have recently had.
RAYOS can cause high
blood pressure, salt and water retention and low blood potassium.
There is an increased risk of developing holes in the stomach or intestines
if you have certain stomach and intestinal disorders.
Behavior and mood changes can occur,
including intense excitement or happiness, sleeplessness, mood swings, personality changes or severe depression.
Long-term use of RAYOS can
cause decreases in bone density.
RAYOS can cause cataracts, eye infections and glaucoma.
Do not receive a “live” vaccine while taking RAYOS. The vaccine may not work as well during this time, and may not fully protect you from
disease.
Taking RAYOS during the first trimester of pregnancy can harm an unborn baby.
Long-term use of RAYOS can slow growth and development in children.
The most common side effects with RAYOS are water retention, high blood sugar, high blood pressure, unusual behavior and mood changes, increased appetite and weight gain.
Please see full prescribing information for RAYOS at www.RAYOSrx.com.
About Horizon Pharma
Horizon Pharma, Inc. (NASDAQ: HZNP) is a biopharmaceutical company
that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. For more information, please visit
www.horizonpharma.com
.
Forward Looking Statements
This press
release contains forward-looking statements, including statements regarding the timing of a potential commercial launch of RAYOS in the United States, the company’s plans to develop a broader commercial strategy for RAYOS and the potential for
RAYOS to provide a new treatment option for patients with inflammatory diseases. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release, and actual results may differ
materially from those in these forward-looking statements as a result of various factors, including, but not limited to, risks regarding the company’s ability to commercialize products successfully, changes in the company’s strategy as to
when to launch RAYOS in the United States and on which approved indications it will focus its initial commercial efforts, whether physicians will prescribe and patients will use RAYOS, once available, and competition in the market for
RAYOS. For a further description of these and other risks facing the company, please see the risk factors described in the company’s filings with the United States Securities and Exchange Commission, including those factors discussed under
the caption “Risk Factors” in those filings. Forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to update or revise these statements, except as may be required by law.
References
|
1.
|
Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis.
2012 May 5. [Epub ahead of print]
|
|
2.
|
Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in
rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008;371:205-214.
|
|
3.
|
Buttgereit F, Doering G, Schaeffler A, et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann
Rheum Dis. 2010;69:1275-1280.
|
###
Contacts
Robert J. De Vaere
Executive Vice President and Chief Financial Officer
investor-relations@horizonpharma.com
Media
Geoff Curtis
DJE Science
312-550-8138
geoff.curtis@djescience.com
Investors
Kathy Galante
Burns McClellan, Inc.
212-213-0006
kgalante@burnsmc.com
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Apr 2023 to Apr 2024
